MannKind completes acquisition of scPharmaceuticals; SCPH to be delisted from Nasdaq
PositiveFinancial Markets

MannKind has successfully completed its acquisition of scPharmaceuticals, a move that is expected to enhance its portfolio and market position. This acquisition is significant as it not only expands MannKind's capabilities but also leads to the delisting of scPharmaceuticals from Nasdaq, marking a new chapter for both companies. This strategic decision reflects MannKind's commitment to growth and innovation in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System